Prostate-specific membrane antigen (PSMA)—an antigen overexpressed on almost all kinds of prostate cancer cell membranes—is considered to be an ideal target for the diagnosis and treatment of prostate cancer [29,30,31]. This evidence concerns the gene FOLH1 and prostate carcinoma.